
Alvotech Provides Update on Corporate Sustainability Framework
Alvotech (Nasdaq: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced an update to the Company’s Corporate Sustainability framework, including the release of key environmental, social and governance (“ESG”) indicators for 2022.
“As part of our commitment to improve the sustainability of healthcare by providing access to more affordable biologic medicines, we recognize that corporate sustainability is closely linked to our long-term success and the value we may bring to patients, healthcare providers and all of our stakeholders,” said Robert Wessman, Founder, Chairman and CEO of Alvotech.
Data on key ESG indicators for 2020-2022 can be found on Alvotech’s dedicated web portal.
Alvotech’s Board of Directors has established a Corporate Sustainability Committee (CSC) to oversee the Company’s strategy as it relates to ESG matters.
Alvotech’s corporate headquarters, purpose-built manufacturing facility and a large part of the Company’s R&D operations are located in Reykjavik, the capital of Iceland. All of the electrical power for the R&D and manufacturing operations is sourced from the local grid, and fully generated from renewable hydro and geothermal sources while heating is provided from renewable geothermal sources.
Alvotech emphasizes gender equality and has received an annual equal pay certification from the Icelandic Directorate of Equality since 2021. While Alvotech’s equality policy is based on Icelandic law, it has been implemented globally for Alvotech employees, applying a company-wide career framework and equal pay standards uniformly.
More information regarding the relationship between biosimilars and sustainability can be found here on Alvotech’s website.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
Forward Looking Statements
Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial or operating performance of Alvotech and may include, for example, Alvotech’s expectations regarding capitalization through equity or debt financing, future growth, results of operations, performance, including cost of product revenue, future capital and other expenditures, competitive advantages, partnerships, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, the potential approval and commercial launch of its product candidates, the timing of the announcement of clinical study results, the commencement of patient studies, regulatory applications, and completion of regulatory review, regulatory approvals and market launches. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against Alvotech or others following the business combination between Alvotech Holdings S.A., Oaktree Acquisition Corp. II and Alvotech; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (5) Alvotech’s estimates of expenses and profitability; (6) Alvotech’s ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (8) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (9) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (10) the ability of Alvotech’s partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (11) Alvotech’s ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (12) the success of Alvotech’s current and future collaborations, joint ventures, partnerships or licensing arrangements; (13) Alvotech’s ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (14) Alvotech’s ability to manufacture sufficient commercial supply of its approved products; (15) the outcome of ongoing and future litigation regarding Alvotech’s products and product candidates; (16) the potential impact of the ongoing COVID-19 pandemic on the FDA’s review timelines, including its ability to complete timely inspection of manufacturing sites; (17) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, war in Ukraine and global geopolitical tension, and the ongoing and evolving COVID-19 pandemic on the Company’s business, financial position, strategy and anticipated milestones; and (18) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication.
CONTACTS
Alvotech Investor Relations and Global Communications
Benedikt Stefansson
alvotech.ir[at]alvotech.com
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Jobindex A/S meddeler sin hensigt om afnotering og tilbud fra Danielsen 2 ApS til aktionærerne om køb af deres aktier til 1.900 kr. pr. aktie2.6.2023 20:16:00 CEST | pressemeddelelse
Selskabsmeddelelse nr. 6 / 2023 København, Danmark 2. juni 2023 – Jobindex A/S (“Jobindex” eller “Selskabet”), meddeler, at Jobindex i dag har besluttet at lade Selskabets aktier slette fra handel og officiel notering fra Nasdaq First North Growth Market Denmark (“Nasdaq First North”) og bemyndiget adm. direktør Kaare Danielsen til at indgive anmodning herom til Nasdaq Copenhagen A/S inden den 1. oktober 2023 samt at Danielsen 2 ApS (“Tilbudsgiver”) fremsætter et frivilligt ureguleret offentligt købstilbud på 1.900 kr. pr. aktie (det “Offentlige Købstilbud”) til alle aktionærer i Jobindex med undtagelse af Tilbudsgiver og Selskabet for så vidt angår egne aktier. For aktionærerne i Jobindex A/S betyder dette, at man har valget imellem at: Acceptere det Offentlige Købstilbud, der indebærer en præmie på ca. 8,6% ift. lukkekursen pr. 2. juni 2023 og en præmie på ca. 9,7% ift. de sidste 12 handelsdages volumenvægtede gennemsnitskurs (VWAP); ellerFortsætte uændret som aktionær i Jobindex A/S
Nokia Corporation: Repurchase of own shares on 02.06.20232.6.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 2 June 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 02.06.2023 Espoo, Finland – On 2 June 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL362,6953.83CEUX1,1353.84AQEU1,6303.81TQEX1,9403.81Total367,4003.83 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 and end
BlueCat acquires network infrastructure monitoring and automation platform Indeni2.6.2023 19:00:00 CEST | Press release
Customers will gain an enhanced ability to maintain network resiliency TORONTO, June 02, 2023 (GLOBE NEWSWIRE) -- BlueCat Networks, a leading provider of mission-critical network and cloud infrastructure software for reliable and secure DNS, DHCP, and IP address management (collectively known as DDI), announced today that it has acquired Indeni. Moelis & Company acted as financial advisors to BlueCat. Financial terms were not disclosed, and the deal is subject to regulatory approval. Indeni’s platform helps network operations (NetOps) teams assure the health of their network appliances such as firewalls, load balancers, and secure web proxies. It analyzes device configurations, metrics, and logs through deep domain expertise, codified as knowledge. And it alerts administrators about existing and potential issues, using a global, crowd-sourced knowledge base to identify and recommend remediation steps using automation. Customers using Check Point, Palo Alto Networks, Fortinet, F5, and m
Aegon completes share buyback2.6.2023 18:00:00 CEST | Press release
The Hague, June 2, 2023 - Aegon has completed its share buyback program, announced on February 9, 2023, aimed at returning EUR 200 million of surplus cash capital to shareholders. Between February 10, 2023 and June 2, 2023, common shares for an amount of EUR 200 million were repurchased. A total of 46,797,567 common shares were repurchased at an average price of EUR 4.2737 per share. Aegon intends to propose at its next Annual General Meeting of shareholders to cancel these repurchased shares. For further details visit our share buyback updates page at aegon.com. About Aegon Aegon is an integrated, diversified, international financial services group. The company offers investment, protection, and retirement solutions, with a strategic focus on three core markets (the United States, the United Kingdom, and the Netherlands), three growth markets (Spain & Portugal, Brazil, and China), and one global asset manager. Aegon's purpose of Helping people live their best lives runs through all it
Vaisala Oyj: SHARE REPURCHASE 2.6.20232.6.2023 17:30:00 CEST | Press release
VAISALA CORPORATIONSTOCK EXCHANGE RELEASE 2.6.2023VAISALA CORPORATION: SHARE REPURCHASE 2.6.2023In the Helsinki Stock ExchangeTrade date 2.6.2023Bourse trade BuyShare VAIASAmount 1 000SharesAverage price/ share 44,0726EURTotal cost 44 072,60EURVaisala Corporation now holds a total of 171 216 sharesincluding the shares repurchased on 2.6.2023On behalf of Vaisala CorporationNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information Paula Liimattatel +358 9 8949 2020, ir@vaisala.comwww.vaisala.com Attachment VAIAS 2.6.2023 trades